SPS
MYGN icon

Susquehanna Portfolio Strategies’s Myriad Genetics MYGN Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Sell
364,154
-19,503
-5% -$102K 0.02% 543
2025
Q4 		$2.36M Hold
383,657
– – 0.04% 464
2025
Q3 		$2.77M Sell
383,657
-72,483
-16% -$430K 0.04% 441
2025
Q2 		$2.42M Buy
+456,140
New +$2.69M 0.05% 334

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna Portfolio Strategies's MYGN Position: Q1 2026 in Review

Susquehanna Portfolio Strategies reduced its Myriad Genetics (MYGN) stake by 5.1% in Q1 2026, selling an estimated $102K and leaving 364,154 shares worth $1.64M. The position accounts for 0.02% of the portfolio, ranked #543.

Susquehanna Portfolio Strategies first reported a position in MYGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.77M in Q3 2025. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Susquehanna Portfolio Strategies held 364,154 shares of Myriad Genetics worth $1.64M as of Q1 2026.
  • Susquehanna Portfolio Strategies sold 19,503 Myriad Genetics shares in Q1 2026, an estimated $102K.
  • Myriad Genetics made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #543 holding.
  • Susquehanna Portfolio Strategies first reported a position in Myriad Genetics in Q2 2025 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's Myriad Genetics position peaked at $2.77M in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.